nach oben

Current Pulmonology Reports

Erschienen in:

01.12.2013 | Interstitial Lung Disease (G Tino, Section editor)

Acute exacerbation of idiopathic pulmonary fibrosis: a proposal

verfasst von: Kerri A. Johannson, Harold R. Collard

Erschienen in: Current Pulmonology Reports | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Acute exacerbation of idiopathic pulmonary fibrosis (IPF) occurs in approximately 10 % of IPF patients annually, and is a leading cause of morbidity and mortality in this disease. Although currently defined as idiopathic acute worsening, acute exacerbation of IPF may in fact have a variety of causes, in particular infection and aspiration. Central to the pathobiology of clinically meaningful events is a diffuse injury to the IPF lung, manifest histopathologically as diffuse alveolar damage, and biologically as accelerated alveolar epithelial cell injury or repair. On the basis of these recent observations, we propose a new conceptual framework for acute exacerbation of IPF that removes the idiopathic requirement and focuses on the pathophysiological mechanism involved.

•• Raghu G et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824. These are the most recent internationally accepted consensus guidelines on the diagnosis and management of IPF.PubMedCrossRef

Collard HR et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176(7):636–43.PubMedCrossRef

•• Song JW et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011;37(2):356–63. This manuscript describes clinical features and outcomes in acute exacerbations of IPF for the largest descriptive cohort to date. It also reveals that acute exacerbation may occur after surgery.PubMedCrossRef

Kondoh Y et al. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest. 1993;103(6):1808–12.PubMedCrossRef

Kondo A, S.S. Acute exacerbation in idiopathic interstitial pneumonia (IIP). Intractable Diseases Research Foundation Publication No. 27. ed. Interstitial pneumonia of unknown etiology. 1989, Tokyo, Japan.: University of Tokyo Press.

King Jr TE et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(1):92–9.PubMedCrossRef

Noble PW et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–9.PubMedCrossRef

Richeldi L et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079–87.PubMedCrossRef

Zisman DA et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010;363(7):620–8.PubMedCrossRef

10.

Mura M et al. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J. 2012;40(1):101–9.PubMedCrossRef

11.

Judge EP et al. Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur Respir J. 2012;40(1):93–100.PubMedCrossRef

12.

Simon-Blancal V et al. Acute exacerbation of idiopathic pulmonary fibrosis: outcome and prognostic factors. Respiration. 2012;83(1):28–35.PubMedCrossRef

13.

Collard HR et al. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res. 2013;14:73.PubMedCrossRef

14.

Olson AL et al. Seasonal variation: mortality from pulmonary fibrosis is greatest in the winter. Chest. 2009;136(1):16–22.PubMedCrossRef

15.

Johannson KA et al. Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure. Eur Respir J. (in press).

16.

Akira M et al. Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;178(4):372–8.PubMedCrossRef

17.

Parambil JG, Myers JL, Ryu JH. Histopathologic features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis undergoing surgical lung biopsy. Chest. 2005;128(5):3310–5.PubMedCrossRef

18.

Churg A et al. Acute exacerbation (acute lung injury of unknown cause) in UIP and other forms of fibrotic interstitial pneumonias. Am J Surg Pathol. 2007;31(2):277–84.PubMedCrossRef

19.

Churg A, Wright JL, Tazelaar HD. Acute exacerbations of fibrotic interstitial lung disease. Histopathology. 2011;58(4):525–30.PubMedCrossRef

20.

Konishi K et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;180(2):167–75.PubMedCrossRef

21.

• Collard HR et al. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2010;299(1):L3–7. This manuscript reports an investigation of the plasma biomarker profile for acute exacerbation of IPF, demonstrating it is predominantly suggestive of increased alveolar epithelial cell injury and/or activity.PubMedCrossRef

22.

Kakugawa T et al. Serum heat shock protein 47 levels are elevated in acute exacerbation of idiopathic pulmonary fibrosis. Cell Stress Chaperones. 2013.

23.

Kahloon RA et al. Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses. Am J Respir Crit Care Med. 2012;187(7):768–75.CrossRef

24.

Huie TJ et al. A detailed evaluation of acute respiratory decline in patients with fibrotic lung disease: aetiology and outcomes. Respirology. 2010;15(6):909–17.PubMedCrossRef

25.

• Wootton SC et al. Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(12):1698–702. This study demonstrated that viral infection is present in a minority of cases of acute exacerbation of IPF.PubMedCrossRef

26.

• Lee JS et al. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J. 2012;39(2):352–8. This study revealed that elevated pepsin levels are present in the bronchoalveolar lavage of patients with acute exacerbation of IPF, suggesting that aspiration is responsible for a subgroup of cases.PubMedCrossRef

27.

Tobin RW et al. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;158(6):1804–8.PubMedCrossRef

28.

Raghu G et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J. 2006;27(1):136–42.PubMedCrossRef

29.

Raghu G et al. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest. 2006;129(3):794–800.PubMedCrossRef

30.

Linden PA et al. Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation. J Thorac Cardiovasc Surg. 2006;131(2):438–46.PubMedCrossRef

31.

• Lee JS et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med. 2013;1(5):369–76. This study revealed that anti-acid therapy may reduce the incidence of acute exacerbation of IPF in a clinical trial cohort.CrossRef

32.

Kondoh Y et al. Acute exacerbation of interstitial pneumonia following surgical lung biopsy. Respir Med. 2006;100(10):1753–9.PubMedCrossRef

33.

Sakamoto S et al. Acute exacerbation of idiopathic interstitial pneumonia following lung surgery in 3 of 68 consecutive patients: a retrospective study. Intern Med. 2011;50(2):77–85.PubMedCrossRef

34.

Sugiura H et al. Acute exacerbation of usual interstitial pneumonia after resection of lung cancer. Ann Thorac Surg. 2012;93(3):937–43.PubMedCrossRef

35.

Suzuki H et al. Risk of acute exacerbation of interstitial pneumonia after pulmonary resection for lung cancer in patients with idiopathic pulmonary fibrosis based on preoperative high-resolution computed tomography. Surg Today. 2011;41(7):914–21.PubMedCrossRef

36.

Yano M et al. Post-operative acute exacerbation of pulmonary fibrosis in lung cancer patients undergoing lung resection. Interact Cardiovasc Thorac Surg. 2012;14(2):146–50.PubMedCrossRef

37.

Mizuno Y et al. The importance of intraoperative fluid balance for the prevention of postoperative acute exacerbation of idiopathic pulmonary fibrosis after pulmonary resection for primary lung cancer. Eur J Cardiothorac Surg. 2012;41(6):e161–5.PubMedCrossRef

38.

Sakamoto K et al. Acute exacerbation of IPF following diagnostic bronchoalveolar lavage procedures. Respir Med. 2012;106(3):436–42.PubMedCrossRef

39.

Ghatol A, Ruhl AP, Danoff SK. Exacerbations in idiopathic pulmonary fibrosis triggered by pulmonary and nonpulmonary surgery: a case series and comprehensive review of the literature. Lung. 2012;190(4):373–80.PubMedCrossRef

40.

Rangappa P, Moran JL. Outcomes of patients admitted to the intensive care unit with idiopathic pulmonary fibrosis. Crit Care Resusc. 2009;11(2):102–9.PubMed

41.

Al-Hameed FM, Sharma S. Outcome of patients admitted to the intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis. Can Respir J. 2004;11(2):117–22.PubMed

42.

Collard HR et al. Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians. Respir Med. 2007;101(9):2011–6.PubMedCrossRef

43.

Horita N et al. Tacrolimus and steroid treatment for acute exacerbation of idiopathic pulmonary fibrosis. Intern Med. 2011;50(3):189–95.PubMedCrossRef

44.

Abe S et al. Polymyxin B-immobilized fiber column (PMX) treatment for idiopathic pulmonary fibrosis with acute exacerbation: a multicenter retrospective analysis. Intern Med. 2012;51(12):1487–91.PubMedCrossRef

45.

Tachibana K et al. Polymyxin-B hemoperfusion for acute exacerbation of idiopathic pulmonary fibrosis: serum IL-7 as a prognostic marker. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28(2):113–22.PubMed

46.

Noma S et al. Two cases of acute exacerbation of interstitial pneumonia treated with polymyxin B-immobilized fiber column hemoperfusion treatment. Intern Med. 2007;46(17):1447–54.PubMedCrossRef

47.

Seo Y et al. Beneficial effect of polymyxin B-immobilized fiber column (PMX) hemoperfusion treatment on acute exacerbation of idiopathic pulmonary fibrosis. Intern Med. 2006;45(18):1033–8.PubMedCrossRef

48.

Oishi K et al. Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of idiopathic pulmonary fibrosis. Cytokine. 2013;61(1):84–9.PubMedCrossRef

49.

Inase N et al. Cyclosporin A followed by the treatment of acute exacerbation of idiopathic pulmonary fibrosis with corticosteroid. Intern Med. 2003;42(7):565–70.PubMedCrossRef

50.

Sakamoto S et al. Cyclosporin A in the treatment of acute exacerbation of idiopathic pulmonary fibrosis. Intern Med. 2010;49(2):109–15.PubMedCrossRef

51.

Kondoh Y et al. Recombinant thrombomodulin in acute exacerbation of idiopathic pulmonary fibrosis, in B102. Interstitial lung disease: novel management and outcome strategies. American Thoracic Society. p. A3811.

52.

Kondoh Y et al. Risk factors of acute exacerbation of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2010;27(2):103–10.PubMed

53.

Moeller A et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179(7):588–94.PubMedCrossRef

54.

Fujimoto K et al. Acute exacerbation of idiopathic pulmonary fibrosis: high-resolution CT scores predict mortality. Eur Radiol. 2012;22(1):83–92.PubMedCrossRef

Titel: Acute exacerbation of idiopathic pulmonary fibrosis: a proposal
verfasst von: Kerri A. Johannson
Harold R. Collard
Publikationsdatum: 01.12.2013
Verlag: Springer US
Erschienen in: Current Pulmonology Reports / Ausgabe 4/2013
Elektronische ISSN: 2199-2428
DOI: https://doi.org/10.1007/s13665-013-0065-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Acute exacerbation of idiopathic pulmonary fibrosis: a proposal

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2013

Combined pulmonary fibrosis and emphysema

The small airways in asthma

GERD and idiopathic pulmonary fibrosis: cause or effect

Management of drug-resistant tuberculosis

Diagnosis and treatment of latent tuberculosis infection: an update

Idiopathic pulmonary fibrosis co-morbidity: thromboembolic disease and coronary artery disease

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin